U
Ugo De Giorgi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 465
Citations - 14798
Ugo De Giorgi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 50, co-authored 358 publications receiving 10145 citations. Previous affiliations of Ugo De Giorgi include Queen Mary University of London & Yahoo!.
Papers
More filters
Journal ArticleDOI
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,David Cella,James Reeves,Robert E. Hawkins,Jun Guo,Paul Nathan,Michael Staehler,Paul de Souza,Jaime R. Merchan,Ekaterini Boleti,Kate Fife,Jie Jin,Robert Jones,Hirotsugu Uemura,Ugo De Giorgi,Ulrika Harmenberg,Jinwan Wang,Cora N. Sternberg,Keith C. Deen,Lauren McCann,Michelle D. Hackshaw,Rocco Crescenzo,Lini Pandite,Toni K. Choueiri +24 more
TL;DR: Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazoSmithKline Pharmaceuticals.
Journal ArticleDOI
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles,Ignacio Duran,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Flechon,Gwenaelle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui,Xiaodong Shen,Christina Louise Derleth,Marjorie C. Green,Alain Ravaud +23 more
TL;DR: Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1, thus precluding further formal statistical analysis.
Journal ArticleDOI
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer,Boris Alekseev,Sun Young Rha,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Evgeny Kopyltsov,María José Méndez-Vidal,Vadim Kozlov,Anna Alyasova,Sung Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jaime R. Merchan,Eric Winquist,Pablo Maroto,Jeffrey C. Goh,Miso Kim,Howard Gurney,Vijay Patel,Avivit Peer,Giuseppe Procopio,Toshio Takagi,Bohuslav Melichar,Frederic Rolland,Ugo De Giorgi,Shirley Wong,Jens Bedke,Manuela Schmidinger,Corina E. Dutcus,Alan D. Smith,Lea Dutta,Kalgi Mody,Rodolfo F. Perini,Dongyuan Xing,Toni K. Choueiri +37 more
TL;DR: In this article, Lenvatinib in combination with pembrolizumab or everolimus has been shown to have activity against advanced renal cell carcinoma (RCC).
Journal ArticleDOI
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini,Thomas Powles,Michael B. Atkins,Bernard Escudier,David F. McDermott,Cristina Suarez,Sergio Bracarda,Walter M. Stadler,Frede Donskov,Jae-Lyun Lee,Robert E. Hawkins,Alain Ravaud,Boris Alekseev,Michael Staehler,Motohide Uemura,Ugo De Giorgi,Begoña Mellado,Camillo Porta,Bohuslav Melichar,Howard Gurney,Jens Bedke,Toni K. Choueiri,Francis Parnis,Tarik Khaznadar,Alpa Thobhani,S. Li,Elisabeth Piault-Louis,Gretchen Frantz,Mahrukh Huseni,Christina Schiff,Marjorie C. Green,Robert J. Motzer +31 more
TL;DR: Results of IMmotion151 support atezolizumab plus bevacIZumab as a first-line treatment option for selected patients with advanced renal cell carcinoma and showed a favourable safety profile.
Journal ArticleDOI
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Matthew D. Galsky,Jose Angel Arranz Arija,Aristotelis Bamias,Ian D. Davis,Maria De Santis,Eiji Kikuchi,Xavier Garcia-del-Muro,Ugo De Giorgi,Marina Mencinger,Kouji Izumi,Stefano Panni,Mahmut Gumus,Mustafa Ozguroglu,Arash Rezazadeh Kalebasty,Se Hoon Park,Boris Alekseev,Fabio A.B. Schutz,Jian Ri Li,Dingwei Ye,Nicholas J. Vogelzang,Sandrine Bernhard,Darren Tayama,Sanjeev Mariathasan,Almut Mecke,Ann Christine Thastrom,Enrique Grande +25 more
TL;DR: The results of IMvigor130 support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial carcinoma and the safety profile of the combination was consistent with that observed with the individual agents.